Sugi Predict

Sugi Predict / Compounds / SCHEMBL3128352

SCHEMBL3128352

SCHEMBL3128352

CC(C)(C)c1ccc(-c2ccccc2C(=O)O)cc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LTB4R2 Q9NPC1 4/20 0.50
▸ BRS3 P32247 2/20 0.50
▸ RORB Q92753 1/20 0.49
▸ AKR1C2 P52895 1/20 0.49
▸ AKR1C1 Q04828 1/20 0.49
▸ HNF4A P41235 1/20 0.49
▸ MYC P01106 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ BCAT2 O15382 1/20 0.47
▸ PPARG P37231 2/20 0.47
▸ CDK4 P11802 1/20 0.46
▸ CCND1 P24385 1/20 0.46
▸ SRD5A2 P31213 1/20 0.46
▸ HCAR2 Q8TDS4 1/20 0.46
▸ NR1H4 Q96RI1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28440024 0.90 RORB (0.48) LTB4R2BRS3RORBAKR1C2AKR1C1
SCHEMBL4941231 0.89 PPARG (0.44) LTB4R2BRS3RORBAKR1C2AKR1C1
SCHEMBL23353984 0.86 TACR1 (0.48) LTB4R2BRS3HNF4AMYCMEN1
SCHEMBL29979035 0.86 TACR1 (0.48) LTB4R2BRS3HNF4AMYCMEN1
SCHEMBL6480249 0.86 TRPV1 (0.53) RORBMEN1KMT2ASMN1; SMN2BCAT2
SCHEMBL294262 0.85 HNF4A (0.67) RORBAKR1C2AKR1C1HNF4AMYC
SCHEMBL20504191 0.85 NR1H4 (0.52) RORBAKR1C2AKR1C1HNF4AMYC
SCHEMBL18759613 0.84 HNF4A (0.63) LTB4R2HNF4AMYCMEN1KMT2A
SCHEMBL30292805 0.84 HNF4A (0.63) LTB4R2HNF4AMYCMEN1KMT2A
SCHEMBL30892680 0.84 BCAT2 (0.65) LTB4R2RORBMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0059983-B1 SUBSTITUTED BIPHENYL COMPOUNDS FOR USE AS A MEDICAMENT THE WELLCOME FOUNDATION LIMITED (GB) 1986-06-11 — — EP claimed
EP-0059983-A1 Substituted biphenyl compounds for use as a medicament THE WELLCOME FOUNDATION LIMITED (GB) 1982-09-15 — — EP claimed
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists BAYER AKTIENGESELLSCHAFT (DE) 2025-08-26 — — US disclosed
EP-4058448-B1 HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER AG (DE) 2024-05-29 — — EP disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 — — US disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 — — US disclosed
EP-4058448-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2022-09-21 — — EP disclosed
CN-110862368-B Photocatalytic oxidation synthesis method of benzocoumarin compound 浙江工业大学 2021-06-15 — — CN disclosed
WO-2021094436-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2021-05-20 — — WO disclosed
WO-2021094436-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2021-05-20 — — WO disclosed
EP-3822268-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2021-05-19 — — EP disclosed
US-20060223851-A1 TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS BERTINATO PETER 2006-10-05 — — US disclosed
US-20050234099-A1 Substituted quinoline compounds PFIZER INC 2005-10-20 — — US disclosed
WO-2005080373-A1 SUBSTITUTED QUINOLINE COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-09-01 — — WO disclosed
CN-1500085-A Lipid lowering biphenylcarboxamides ղɭҩҵ���޹�˾ 2004-05-26 — — CN disclosed
EP-1379515-A1 LIPID LOWERING BIPHENYLCARBOXAMIDES JANSSEN PHARMACEUTICA N.V. (BE) 2004-01-14 — — EP disclosed
WO-2002081460-A1 LIPID LOWERING BIPHENYLCARBOXAMIDES JANSSEN PHARMACEUTICA N.V. (BE) 2002-10-17 — — WO disclosed
EP-0059983-B1 SUBSTITUTED BIPHENYL COMPOUNDS FOR USE AS A MEDICAMENT THE WELLCOME FOUNDATION LIMITED (GB) 1986-06-11 — — EP disclosed
US-4578522-A CHEMICAL INTERMEDIATES FOR BLOOD LIPID CONTROLLING COMPOUNDS BURROUGHS WELLCOME CO. 1986-03-25 — — US disclosed
EP-0059983-A1 Substituted biphenyl compounds for use as a medicament THE WELLCOME FOUNDATION LIMITED (GB) 1982-09-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists ADAMTS7, MMP7, ADAM17 LTB4R2 1814/4885BRS3 160/4885RORB 4773/4885
US-20050234099-A1 Substituted quinoline compounds APOB, APOL1, MTPN LTB4R2 1287/4885BRS3 1896/4885RORB 1741/4885
US-20060223851-A1 TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS APOB, MTPN, CTRB1 LTB4R2 830/4885BRS3 440/4885RORB 1873/4885
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAM17 LTB4R2 1814/4885BRS3 160/4885RORB 4773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.